Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents.


The IMPAACT 2017 is a Phase I/II study being conducted to establish if adolescents (and later younger children), infected with HIV-1 who are currently virologically suppressed on ART, remain suppressed upon switching to a two-drug intramuscular (IM) long-acting (LA) regimen of CAB LA plus RPV LA. The initial age group studied will be adolescents aged 12 to < 18 years and results from this initial age cohort may inform the study details in a protocol amendment at a later date for a younger population.


  • Dr Faeezah Patel, Principal Investigator
  • Dr Lee Fairlie, Sub Investigator
  • Dr Elizea Horne, Sub Investigator
  • Dr Mrinmayee Dhar, Sub Investigator
  • Dr Muneerah Khan, Sub Investigator
  • Dr Pemphero Chasela, Sub Investigator
  • Dr Jeanne Coetzee, Sub Investigator

Latest Update

April 2024

For more about IMPAACT 2017 please email

Stay up to date

Get updates on news, resources, events and happenings from Wits RHI.